In the latest trading session, 0.73 million Marinus Pharmaceuticals Inc (NASDAQ:MRNS) shares changed hands as the company’s beta touched 1.19. With the company’s most recent per share price at $0.30 changed hands at -$0.03 or -8.19% at last look, the market valuation stands at $16.67M. MRNS’s current price is a discount, trading about -3653.33% off its 52-week high of $11.26. The share price had its 52-week low at $0.26, which suggests the last value was 13.33% up since then. When we look at Marinus Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.83 million shares, with the 3-month average coming to 2.54 million.
Analysts gave the Marinus Pharmaceuticals Inc (MRNS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.56. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended MRNS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Marinus Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS was in red as seen in intraday trades today. With action -6.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -97.22%, with the 5-day performance at -6.72% in the red. However, in the 30-day time frame, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is -7.88% down. Looking at the short shares, we see there were 5.66 million shares sold at short interest cover period of 1.09 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need an upside of 90.0% from its recent market value. According to analyst projections, MRNS’s forecast low is 2 with 6 as the target high. To hit the forecast high, the stock’s price needs a -1900.0% plunge from its current level, while the stock would need to soar -566.67% for it to hit the projected low.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Data shows that the Marinus Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -79.02% over the past 6 months, a 22.81% in annual growth rate that is considerably higher than the industry average of 16.60%. Year-over-year growth is forecast to reach 12.20% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 10.33M. 4 analysts are of the opinion that Marinus Pharmaceuticals Inc’s revenue for the current quarter will be 10.48M. The company’s revenue for the corresponding quarters a year ago was 7.19M and 7.68M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 43.74%. The estimates for the next quarter sales put growth at 36.53%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 6.04%. The 2024 estimates are for Marinus Pharmaceuticals Inc earnings to increase by 22.86%, but the outlook for the next 5-year period is at 20.00% per year.
MRNS Dividends
Marinus Pharmaceuticals Inc is expected to release its next quarterly earnings report in January.
Marinus Pharmaceuticals Inc (NASDAQ:MRNS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.94% of Marinus Pharmaceuticals Inc shares while 83.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 93.24%. There are 83.04% institutions holding the Marinus Pharmaceuticals Inc stock share, with TANG CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 8.443% of the shares, roughly 4.8 million MRNS shares worth $5.62 million.
SOFINNOVA INVESTMENTS, INC. holds the second largest percentage of outstanding shares, with 7.3025% or 4.15 million shares worth $4.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors. With 1.73 shares estimated at $0.52 million under it, the former controlled 3.14% of total outstanding shares. On the other hand, abrdn Healthcare Investors held about 2.78% of the shares, roughly 1.53 shares worth around $0.46 million.
